1
LMY-920 for Treatment of Relapsed or Refractory Myeloma
Condition(s):Multiple Myeloma, Refractory; Multiple Myeloma in RelapseLast Updated:January 13, 2023Not yet recruiting
Refractory Myeloma: 1208 Clinical Trials, Page 1 of 121
Hide Studies Not Open or Pending
2
Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma
Condition(s):Relapse and / or Refractory MyelomaLast Updated:June 7, 2018Unknown status
3
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Condition(s):Multiple MyelomaLast Updated:February 7, 2018Terminated
4
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:August 30, 2017Completed
5
Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma
Condition(s):Relapse Multiple MyelomaLast Updated:November 6, 2017Unknown status
6
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:September 25, 2023Not yet recruiting
7
Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:August 28, 2023Completed
8
NMP in Relapsed / Refractory Myeloma
Condition(s):Multiple MyelomaLast Updated:May 5, 2022Completed
9
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
Condition(s):Multiple MyelomaLast Updated:April 14, 2023Recruiting
10
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Condition(s):Recurrent Multiple Myeloma; Refractory Multiple MyelomaLast Updated:September 8, 2023Recruiting